TISSUE REPAIR LIMITED (TRP) - Revolutionizing Wound Healing: Co-founder & CEO Tony Charara on TR987® Clinical Trials and TGA-Approved TR Pro+™

ASX BRIEFS

Send us a text

What if a simple biological trick could revolutionize wound healing for the first time in 25 years? In our latest episode of ASX Briefs, we sit down with Tony Charara, the visionary co-founder and CEO of Tissue Repair Limited, to discuss this groundbreaking innovation. Tony introduces their lead drug candidate, TR987® , which is poised to transform the treatment of chronic wounds as it enters phase three clinical trials in the US and Australia. He explains how decoy yeast cells can accelerate the body’s natural healing processes, potentially making TR987® the first approved drug in its category in a quarter-century.
But that's not all—Tony also sheds light on the recent TGA approval of TR Pro+™, , a post-procedure topical gel that's already creating buzz in over 200 clinics. Initially launched as a cosmetic, TR Pro+™, has shown remarkable results in enhancing skin quality and speeding up recovery post-aesthetic procedures. With its new TGA listing, this product's potential applications have expanded dramatically, from treating acute wounds to addressing conditions like solar keratosis. Tune in to discover the innovative path Tissue Repair Limited is forging and the significant impact their solutions could have on healthcare.